280 related articles for article (PubMed ID: 19078924)
21. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
Nout RA; Bosse T; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; van Eijk R; Ter Haar NT; Smit VT
Gynecol Oncol; 2012 Sep; 126(3):466-73. PubMed ID: 22609107
[TBL] [Abstract][Full Text] [Related]
22. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
23. Current treatment of metastatic endometrial cancer.
Temkin SM; Fleming G
Cancer Control; 2009 Jan; 16(1):38-45. PubMed ID: 19078928
[TBL] [Abstract][Full Text] [Related]
24. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
25. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.
Byron SA; Gartside MG; Wellens CL; Mallon MA; Keenan JB; Powell MA; Goodfellow PJ; Pollock PM
Cancer Res; 2008 Sep; 68(17):6902-7. PubMed ID: 18757403
[TBL] [Abstract][Full Text] [Related]
27. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.
Peterson LM; Kipp BR; Halling KC; Kerr SE; Smith DI; Distad TJ; Clayton AC; Medeiros F
Int J Gynecol Pathol; 2012 May; 31(3):195-205. PubMed ID: 22498935
[TBL] [Abstract][Full Text] [Related]
28. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
[TBL] [Abstract][Full Text] [Related]
29. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors.
Abal M; Planaguma J; Gil-Moreno A; Monge M; Gonzalez M; Baro T; Garcia A; Castellvi J; Ramon Y Cajal S; Xercavins J; Alameda F; Reventos J
Histol Histopathol; 2006 Feb; 21(2):197-204. PubMed ID: 16329044
[TBL] [Abstract][Full Text] [Related]
30. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.
Husseinzadeh N; Husseinzadeh HD
Gynecol Oncol; 2014 May; 133(2):375-81. PubMed ID: 24556063
[TBL] [Abstract][Full Text] [Related]
31. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
32. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
Velasco A; Bussaglia E; Pallares J; Dolcet X; Llobet D; Encinas M; Llecha N; Palacios J; Prat J; Matias-Guiu X
Hum Pathol; 2006 Nov; 37(11):1465-72. PubMed ID: 16949921
[TBL] [Abstract][Full Text] [Related]
33. Molecular pathology of endometrial carcinoma.
Matias-Guiu X; Prat J
Histopathology; 2013 Jan; 62(1):111-23. PubMed ID: 23240673
[TBL] [Abstract][Full Text] [Related]
34. Molecular and pathologic aspects of endometrial carcinogenesis.
Hecht JL; Mutter GL
J Clin Oncol; 2006 Oct; 24(29):4783-91. PubMed ID: 17028294
[TBL] [Abstract][Full Text] [Related]
35. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics.
Risinger JI; Hayes K; Maxwell GL; Carney ME; Dodge RK; Barrett JC; Berchuck A
Clin Cancer Res; 1998 Dec; 4(12):3005-10. PubMed ID: 9865913
[TBL] [Abstract][Full Text] [Related]
36. Endometrial Carcinoma: Specific Targeted Pathways.
Eritja N; Yeramian A; Chen BJ; Llobet-Navas D; Ortega E; Colas E; Abal M; Dolcet X; Reventos J; Matias-Guiu X
Adv Exp Med Biol; 2017; 943():149-207. PubMed ID: 27910068
[TBL] [Abstract][Full Text] [Related]
37. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.
Risinger JI; Maxwell GL; Chandramouli GV; Jazaeri A; Aprelikova O; Patterson T; Berchuck A; Barrett JC
Cancer Res; 2003 Jan; 63(1):6-11. PubMed ID: 12517768
[TBL] [Abstract][Full Text] [Related]
38. Molecule-targeted agents in endometrial cancer.
Delmonte A; Sessa C
Curr Opin Oncol; 2008 Sep; 20(5):554-9. PubMed ID: 19106660
[TBL] [Abstract][Full Text] [Related]
39. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
40. Causes and consequences of microsatellite instability in endometrial carcinoma.
Gurin CC; Federici MG; Kang L; Boyd J
Cancer Res; 1999 Jan; 59(2):462-6. PubMed ID: 9927063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
